(Q43666869)

25 November 2017

0 references

1 reference

title

Lamivudine for hepatitis B after liver transplantation (English)

1 reference

25 November 2017

main subject

liver transplantation

1 reference

1 reference

Mutimer D

1

1 reference

25 November 2017

publication date

1 June 2001

1 reference

25 November 2017

published in

Liver Transplantation

1 reference

25 November 2017

volume

7

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

511-512

1 reference

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Lamivudine treatment for acute hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24934

21 January 2018

Identifiers

DOI

10.1053/JLTS.2001.24934

1 reference

25 November 2017

1 reference